Citadel Advisors’s Prestige Consumer Healthcare PBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.9M Sell
183,440
-60,221
-25% -$3.91M ﹤0.01% 3136
2025
Q4
$15M Buy
243,661
+197,156
+424% +$12.1M ﹤0.01% 2702
2025
Q3
$2.9M Buy
+46,505
New +$3.24M ﹤0.01% 5359
2025
Q2
Sell
-21,291
Closed -$1.83M 14401
2025
Q1
$1.83M Buy
21,291
+6,958
+49% +$571K ﹤0.01% 5700
2024
Q4
$1.12M Sell
14,333
-8,132
-36% -$631K ﹤0.01% 6774
2024
Q3
$1.62M Sell
22,465
-78,657
-78% -$5.57M ﹤0.01% 5907
2024
Q2
$6.96M Sell
101,122
-89,905
-47% -$6.09M ﹤0.01% 3270
2024
Q1
$13.9M Buy
191,027
+170,031
+810% +$11.4M ﹤0.01% 2493
2023
Q4
$1.29M Sell
20,996
-103,545
-83% -$6.15M ﹤0.01% 6186
2023
Q3
$7.12M Buy
124,541
+68,328
+122% +$4.13M ﹤0.01% 3126
2023
Q2
$3.34M Sell
56,213
-5,681
-9% -$340K ﹤0.01% 4281
2023
Q1
$3.88M Sell
61,894
-9,737
-14% -$608K ﹤0.01% 4225
2022
Q4
$4.48M Buy
71,631
+33,835
+90% +$1.94M ﹤0.01% 4040
2022
Q3
$1.88M Sell
37,796
-15,513
-29% -$859K ﹤0.01% 5704
2022
Q2
$3.13M Sell
53,309
-112,042
-68% -$6.18M ﹤0.01% 4678
2022
Q1
$8.75M Buy
165,351
+96,891
+142% +$5.59M ﹤0.01% 3171
2021
Q4
$4.15M Buy
68,460
+42,875
+168% +$2.55M ﹤0.01% 4667
2021
Q3
$1.44M Sell
25,585
-17,957
-41% -$986K ﹤0.01% 7197
2021
Q2
$2.27M Sell
43,542
-2,554
-6% -$123K ﹤0.01% 6282
2021
Q1
$2.03M Sell
46,096
-20,461
-31% -$860K ﹤0.01% 6343
2020
Q4
$2.32M Buy
66,557
+29,997
+82% +$1.07M ﹤0.01% 5048
2020
Q3
$1.33M Sell
36,560
-41,937
-53% -$1.56M ﹤0.01% 5499
2020
Q2
$2.95M Buy
78,497
+18,960
+32% +$758K ﹤0.01% 3898
2020
Q1
$2.18M Sell
59,537
-11,923
-17% -$463K ﹤0.01% 3996
2019
Q4
$2.89M Buy
71,460
+26,486
+59% +$988K ﹤0.01% 3831
2019
Q3
$1.56M Buy
44,974
+30,625
+213% +$1.01M ﹤0.01% 4864
2019
Q2
$455K Sell
14,349
-150,096
-91% -$4.46M ﹤0.01% 6969
2019
Q1
$4.92M Sell
164,445
-118,163
-42% -$3.39M ﹤0.01% 3026
2018
Q4
$8.73M Sell
282,608
-75,787
-21% -$2.77M ﹤0.01% 2066
2018
Q3
$13.6M Buy
358,395
+29,131
+9% +$1.1M 0.01% 1766
2018
Q2
$12.6M Buy
329,264
+109,402
+50% +$3.69M 0.01% 1707
2018
Q1
$7.41M Buy
219,862
+124,560
+131% +$4.78M ﹤0.01% 2023
2017
Q4
$4.23M Buy
95,302
+89,133
+1,445% +$4.06M ﹤0.01% 2676
2017
Q3
$309K Sell
6,169
-90,217
-94% -$4.61M ﹤0.01% 6022
2017
Q2
$5.09M Buy
96,386
+47,053
+95% +$2.52M ﹤0.01% 2107
2017
Q1
$2.74M Sell
49,333
-47,052
-49% -$2.6M ﹤0.01% 2698
2016
Q4
$5.02M Buy
96,385
+42,140
+78% +$2.03M 0.01% 2001
2016
Q3
$2.62M Buy
+54,245
New +$2.74M ﹤0.01% 2655
2016
Q2
Sell
-54,108
Closed -$2.89M 7239
2016
Q1
$2.89M Buy
+54,108
New +$2.66M ﹤0.01% 2284
2015
Q2
Sell
-100,022
Closed -$4.29M 8976
2015
Q1
$4.29M Buy
100,022
+88,984
+806% +$3.39M ﹤0.01% 2187
2014
Q4
$383K Buy
+11,038
New +$366K ﹤0.01% 5092
2014
Q3
Sell
-65,640
Closed -$2.22M 8325
2014
Q2
$2.22M Buy
65,640
+26,657
+68% +$854K ﹤0.01% 2634
2014
Q1
$1.06M Sell
38,983
-2,151
-5% -$63.9K ﹤0.01% 3341
2013
Q4
$1.47M Sell
41,134
-59,621
-59% -$1.98M ﹤0.01% 2837
2013
Q3
$3.04M Sell
100,755
-78,929
-44% -$2.58M ﹤0.01% 2019
2013
Q2
$5.24M Buy
+179,684
New +$5.07M 0.01% 1531

Other funds holding PBH

Citadel Advisors's PBH Position: Q1 2026 in Review

Citadel Advisors reduced its Prestige Consumer Healthcare (PBH) stake by 25% in Q1 2026, selling an estimated $3.91M and leaving 183,440 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3136.

Citadel Advisors first reported a position in PBH in Q2 2013 and has held it in 46 quarters since. The position peaked at $15M in Q4 2025. 355 funds tracked by Wall St. Rank hold PBH as of Q1 2026.

  • Citadel Advisors held 183,440 shares of Prestige Consumer Healthcare worth $10.9M as of Q1 2026.
  • Citadel Advisors sold 60,221 Prestige Consumer Healthcare shares in Q1 2026, an estimated $3.91M.
  • Prestige Consumer Healthcare made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3136 holding.
  • Citadel Advisors first reported a position in Prestige Consumer Healthcare in Q2 2013 and has held it in 46 quarters since.
  • Citadel Advisors's Prestige Consumer Healthcare position peaked at $15M in Q4 2025.
  • 355 funds tracked by Wall St. Rank held Prestige Consumer Healthcare as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.